24-Jul-2026
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
PRNewswire (Wed, 22-Jul 7:00 AM ET)
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test
PRNewswire (Tue, 14-Jul 4:30 PM ET)
PRNewswire (Thu, 9-Jul 7:00 AM ET)
PRNewswire (Thu, 25-Jun 4:30 PM ET)
PRNewswire (Tue, 23-Jun 7:01 AM ET)
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Fri, 19-Jun 7:00 AM ET)
PRNewswire (Tue, 16-Jun 7:00 AM ET)
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
PRNewswire (Wed, 13-May 7:00 AM ET)
PRNewswire (Tue, 12-May 7:00 AM ET)
PRNewswire (Tue, 5-May 7:00 AM ET)
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Castle Biosciences trades on the NASDAQ stock market under the symbol CSTL.
As of July 24, 2026, CSTL stock price declined to $24.68 with 382,886 million shares trading.
CSTL has a beta of -0.08, meaning it tends to be less sensitive to market movements. CSTL has a correlation of 0.00 to the broad based SPY ETF.
CSTL has a market cap of $747.86 million. This is considered a Small Cap stock.
Last quarter Castle Biosciences reported $84 million in Revenue and -$.49 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.01.
In the last 3 years, CSTL traded as high as $44.28 and as low as $12.07.
The top ETF exchange traded funds that CSTL belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
CSTL has outperformed the market in the last year with a price return of +50.2% while the SPY ETF gained +17.7%. However, in the short term, CSTL had mixed performance relative to the market. It has underperformed in the last 3 months, returning +0.9% vs +3.8% return in SPY. But in the last 2 weeks, CSTL shares have fared better than the market returning +4.1% compared to SPY -2.1%.
CSTL support price is $24.67 and resistance is $26.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CSTL shares will trade within this expected range on the day.
